社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
艾迪康控股(09860)
5.100
-0.170
-3.23%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
大家一起腾飞
·
01-15 15:58
$艾迪康控股(09860)$
随着 AI 医疗政策红利释放与技术成熟,艾迪康正从传统第三方检验机构向AI 驱动的智慧医疗服务商转型,有望在千亿级精准医疗市场中占据重要地位。
$艾迪康控股(09860)$ 随着 AI 医疗政策红利释放与技术成熟,艾迪康正从传统第三方检验机构向AI 驱动的智慧医疗服务商转型,有望在千亿级精准医疗市...
回复
评论
点赞
1
编组 21备份 2
分享
举报
虎哥爱老虎油
·
01-06
$艾迪康控股(09860)$
低渗透率高增长:中国诊断服务市场CAGR 15%以上,艾迪康行业地位巩固,抢占脑机接口红利
$诚益通(300430)$
$艾迪康控股(09860)$ 低渗透率高增长:中国诊断服务市场CAGR 15%以上,艾迪康行业地位巩固,抢占脑机接口红利$诚益通(300430)$
回复
评论
点赞
2
编组 21备份 2
分享
举报
方新侠YY
·
2025-12-30
$艾迪康控股(09860)$
在底部区域分批买,在顶部区域分批卖,好过纠结于具体某一个点位的完美。
$艾迪康控股(09860)$ 在底部区域分批买,在顶部区域分批卖,好过纠结于具体某一个点位的完美。
回复
1
点赞
1
编组 21备份 2
分享
举报
外资不跑
·
2025-12-23
$艾迪康控股(09860)$
AI医疗看病比人准,每次从医院回来,我都要去deepseek问一下医生给开的药对不对。
$艾迪康控股(09860)$ AI医疗看病比人准,每次从医院回来,我都要去deepseek问一下医生给开的药对不对。
回复
评论
点赞
1
编组 21备份 2
分享
举报
艾迪康
·
2025-12-31
坚守高品质,共促新发展|艾迪康旗下元德友勤实验室顺利通过 CNAS ISO 15189 复评审
2025年12月19日至21日,苏州元德友勤医学检验实验室成功接受并通过中国合格评定国家认可委员会(CNAS)组织的ISO 15189 医学实验室质量与能力复评审。这是该实验室第三次获得此项权威认可,标志着其质量管理体系与技术服务能力持续符合国际标准,具备稳定可靠的医学检验服务水平。 关于ISO 15189 ISO 15189 是全球医学实验室质量与能力的核心认可标准,覆盖样本接收、检验实施、报告出具全流程,对人员资质、设备管理、检验方法、质量控制、生物安全、信息管理等关键环节均有明确规范,是保障检验结果准确性、可靠性的重要依据,也是医学检验机构专业化、规范化运营的重要标志。 复评审实施情况 本次复评审由主任评审员、安徽医科大学第一附属医院李涛教授,技术评审员、广州中医药大学第一附属医院刘基铎教授,技术评审员、南京大学医学院附属苏州医院严茹红教授组成评审组,依据 CNAS-CL02:2023《医学实验室质量和能力认可准则》及相关应用要求开展全面评审。 ▲评审现场 评审启动会上,评审组组长李涛教授介绍了评审范围、流程及纪律要求,苏州元德友勤医学检验实验室总经理陈军先生和实验室主任岑建农先生分别就实验室概况及 ISO 15189质量管理体系的建设与运行情况作了汇报,并表示将全力配合评审工作,认真落实专家提出的改进建议。 评审期间,专家组通过查阅实验室质量管理体系文件、设备校准记录、人员培训档案、质量控制数据等相关资料,深入实验室各操作区域,实地考察设施环境、实验操作流程,并进行现场提问与实操考核,全面评估了检验前、中、后各环节的质量控制情况。此外,评审组还走访了两家合作医疗机构,了解样品采集、传递、报告反馈等环节的衔接情况,听取临床医护人员对实验室服务质量的评价,进一步验证了实验室在终端服务中的专业表现。 ▲现场评审及走访合作医疗机构 经全面评审
坚守高品质,共促新发展|艾迪康旗下元德友勤实验室顺利通过 CNAS ISO 15189 复评审
# 【年度复盘】收官在即!聊聊今年的投资
精彩
lilk2road:
质量稳如泰山,艾迪康真牛!
回复
1
点赞
1
编组 21备份 2
分享
举报
方新侠YY
·
2025-12-16
$艾迪康控股(09860)$
高盛喊话诊断板块回暖,艾迪康是同行里业绩最好的
$艾迪康控股(09860)$ 高盛喊话诊断板块回暖,艾迪康是同行里业绩最好的
回复
评论
点赞
1
编组 21备份 2
分享
举报
向阳花之光
·
2025-12-09
$艾迪康控股(09860)$
砸2亿美金拿下全球肿瘤CRO巨头冠科生物,直接切入药物研发黄金赛道!
$艾迪康控股(09860)$ 砸2亿美金拿下全球肿瘤CRO巨头冠科生物,直接切入药物研发黄金赛道!
回复
评论
点赞
1
编组 21备份 2
分享
举报
六爷说股
·
2025-12-11
强强联合!艾迪康与**云深化合作,“技术+场景”共筑智慧医疗新生态
12月8日,杭州艾迪康医学检验中心有限公司(以下简称“艾迪康”)与**云计算技术有限公司(以下简称“**云”)在**练秋湖相聚并签署框架合作协议,艾迪康副总裁及首席信息官罗震、艾迪康副总裁及营销中心负责人葛顺、**云中国区公有云解决方案销售部部长庄乾锋等共同出席本次签约仪式。 双方围绕医疗行业数字化转型痛点、AI技术赋能临床质控等场景展开深入探讨,充分交流了在企业数字化建设、AI技术医疗场景应用等方面的经验与见解。 **云中国区公有云解决方案销售部部长庄乾锋表示,**云始终以“技术驱动、开放共赢”为使命,致力于为千行百业提供领先的数字化解决方案。杭州艾迪康作为医疗健康领域的创新先锋,在精准医疗与智能化服务领域成果卓著。此次合作,是双方对“技术赋能产业”这一愿景的深度契合。通过**云的云计算、AI及大数据能力,与艾迪康的行业专长结合,我们必将为医疗行业打造更高效、更智能的数字化转型范式。 **云中国区公有云解决方案销售部部长庄乾锋 艾迪康副总裁及首席信息官罗震表示,“数字化转型正在重塑医疗行业的服务范式。我们期待通过此次合作,构建集数据安全治理、智能算法引擎与云端协同能力于一体的新一代医疗平台,使前沿技术深度赋能临床实践,提升医疗服务的可及性、准确性与普惠价值。” 艾迪康副总裁及首席信息官罗震 **云咨询首席专家王健对**AI战略与行业实践成果做了分享,系统阐述了**云服务、**AI等基础设施在各行业的赋能价值,为双方后续合作搭建了清晰的技术路径。 签约现场,艾迪康公司发布了基于**云技术支撑的艾迪康医疗AI大模型“问医”及智能体应用产品方案。这是艾迪康“场景验证”能力与**云“技术赋能”优势深度融合的成果,充分体现了艾迪康在AI医疗创新应用方面的前瞻布局与高效落地能力。 此次合作是艾迪康与**云深化互信、推进业务合作的重要里程碑,不仅实现了双方在技术、管理、市场等多维度的全
强强联合!艾迪康与**云深化合作,“技术+场景”共筑智慧医疗新生态
回复
评论
点赞
1
编组 21备份 2
分享
举报
方新侠YY
·
2025-12-05
$艾迪康控股(09860)$
这一秒不放弃,下一秒就有希望。
$艾迪康控股(09860)$ 这一秒不放弃,下一秒就有希望。
回复
评论
点赞
1
编组 21备份 2
分享
举报
艾迪康
·
2025-12-11
艾迪康与**云深化合作,共筑“技术+场景”驱动的智慧医疗新生态
12月8日,杭州艾迪康医学检验中心有限公司(以下简称“艾迪康”)与**云计算技术有限公司(以下简称“**云”)正式签署合作协议。艾迪康副总裁及首席信息官罗震、副总裁及营销中心负责人葛顺等公司高管,与**中国区公有云解决方案部部长庄乾锋等高层代表共同出席签约仪式并进行深度对话,标志着双方在智慧医疗领域的协同创新步入全新阶段。 ▲艾迪康副总裁及首席信息官罗震 ▲**中国区公有云解决方案部部长庄乾锋 当前,医疗健康产业正处在数字化转型的关键时期,艾迪康与**云此次携手合作,共同开启了以AI技术为引擎的智慧医疗新篇章。此次合作不仅是技术能力与行业场景的深度融合,更是医学检验服务从传统模式向智能化、生态化演进的重要里程碑。 创新驱动:共建医疗数字化新基座 在人工智能技术加速重构医疗体系的今天,艾迪康始终站在行业创新的前沿。依托在医学检验领域超过二十年的专业积淀,艾迪康拥有覆盖全国的服务网络与多维度临床数据资源。此次与**云达成合作,旨在共同打造面向未来的医疗智能化基础设施。 艾迪康副总裁及首席信息官罗震表示:“数字化转型正在重塑医疗行业的服务范式。我们期待通过此次合作,构建集数据安全治理、智能算法引擎与云端协同能力于一体的新一代医疗平台,使前沿技术深度赋能临床实践,提升医疗服务的可及性、准确性与普惠价值。” ▲签约领导合影 协同成果:技术赋能引领服务升级 基于双方在技术积累与场景探索上的长期准备,本次合作已实现阶段性成果。签约仪式现场,艾迪康正式发布了基于**云技术支持的“问医”医疗大模型及多款智能体解决方案。这些成果是艾迪康“场景验证”能力与**云“技术赋能”优势深度融合的体现,展现了艾迪康在AI医疗创新应用上的前瞻布局与高效实施能力。 智能质控系统可对检验全流程进行实时监测与预警,借助AI算法自动识别数据异常,显著提升
艾迪康与**云深化合作,共筑“技术+场景”驱动的智慧医疗新生态
# 老虎财报季
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
公司概况
公司名称
艾迪康控股
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.adicon.com.cn
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
艾迪康控股有限公司是一家主要提供独立医学实验室(ICL)的控股公司。该公司提供医学检验、临床试验、科研服务、健康管理及病理会诊服务。该公司重点发展感染性疾病、妇女健康、实体肿瘤、围产&儿童中心、血液等核心疾病领域,覆盖内科、儿科、妇产科、肿瘤科、神经科等众多科目。
2025-09-04
半年度报告
2025 中期报告
2025 中期报告
2025-08-22
半年度报告
截至2025年6月30日止六个月之中期业绩公告
截至2025年6月30日止六个月之中期业绩公告
2025-05-23
须予披露的交易
补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权
补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权
2025-05-06
须予披露的交易
须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权
须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权
2025-05-05
股份购回
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告
2025-04-25
年度报告
2024 年度报告
2024 年度报告
2025-03-31
年度报告
截至2024年12月31日止年度之年度业绩公告
截至2024年12月31日止年度之年度业绩公告
2024-09-19
半年度报告
2024 中期报告
2024 中期报告
2024-08-30
半年度报告
截至2024年6月30日止六个月之中期业绩公告
截至2024年6月30日止六个月之中期业绩公告
2024-04-29
股份购回
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告
建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告
2024-04-29
年度报告
2023 年度报告
2023 年度报告
2024-03-28
年度报告
截至2023年12月31日止年度之年度业绩公告
截至2023年12月31日止年度之年度业绩公告
2023-09-25
半年度报告
2023 中期报告
2023 中期报告
2023-08-23
半年度报告
截至2023年6月30日止六个月之中期业绩公告
截至2023年6月30日止六个月之中期业绩公告
2023-06-19
股份发售
绿色申请表格
绿色申请表格
分时
5日
日
周
月
数据加载中...
最高
5.390
今开
5.280
量比
0.57
最低
5.080
昨收
5.270
换手率
0.23%
热议股票
{"pagemeta":{"title":"艾迪康控股(09860)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾迪康控股(09860)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾迪康控股,09860,艾迪康控股股票,艾迪康控股股票老虎,艾迪康控股股票老虎国际,艾迪康控股行情,艾迪康控股股票行情,艾迪康控股股价,艾迪康控股股市,艾迪康控股股票价格,艾迪康控股股票交易,艾迪康控股股票购买,艾迪康控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾迪康控股(09860)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾迪康控股(09860)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"community","symbol":"09860","data":{"stockData":{"symbol":"09860","market":"HK","secType":"STK","nameCN":"艾迪康控股","latestPrice":5.1,"timestamp":1768550905007,"preClose":5.27,"halted":0,"volume":1648000,"delay":0,"changeRate":-0.032258064516129024,"floatShares":726000000,"shares":726000000,"eps":0.065173,"marketStatus":"休市中","change":-0.17,"latestTime":"01-16 16:08:25","open":5.28,"high":5.39,"low":5.08,"amount":8594580,"amplitude":0.058824,"askPrice":5.14,"askSize":1000,"bidPrice":5.1,"bidSize":12500,"shortable":3,"etf":0,"ttmEps":-0.04196,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768786200000},"marketStatusCode":7,"adr":0,"listingDate":1688054400000,"exchange":"SEHK","adjPreClose":5.27,"openAndCloseTimeList":[[1768527000000,1768536000000],[1768539600000,1768550400000]],"volumeRatio":0.566635,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":{"bottom":false,"list":[{"cardType":"TWEET","cardId":"TWEET.522128373645560","cardData":[{"tweetId":"522128373645560","author":{"authorId":"4214309139754652","idStr":"4214309139754652","name":"大家一起腾飞","avatar":"https://static.tigerbbs.com/5249b79edd5e88100a5e593c3ac39bc5","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>随着 AI 医疗政策红利释放与技术成熟,艾迪康正从传统第三方检验机构向AI 驱动的智慧医疗服务商转型,有望在千亿级精准医疗市场中占据重要地位。","plainDigest":"$艾迪康控股(09860)$ 随着 AI 医疗政策红利释放与技术成熟,艾迪康正从传统第三方检验机构向AI 驱动的智慧医疗服务商转型,有望在千亿级精准医疗市场中占据重要地位。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1768463922988,"gmtModify":1768463925093,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":16,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/522128373645560","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":148,"displayRows":4,"foldSize":0,"authorId":"4214309139754652"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.519020428329376","cardData":[{"tweetId":"519020428329376","author":{"authorId":"4214309434755002","idStr":"4214309434755002","name":"虎哥爱老虎油","avatar":"https://static.tigerbbs.com/90161930b2951996910520cfe45ee4d5","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>低渗透率高增长:中国诊断服务市场CAGR 15%以上,艾迪康行业地位巩固,抢占脑机接口红利<a href=\"https://laohu8.com/S/300430\">$诚益通(300430)$ </a>","plainDigest":"$艾迪康控股(09860)$ 低渗透率高增长:中国诊断服务市场CAGR 15%以上,艾迪康行业地位巩固,抢占脑机接口红利$诚益通(300430)$","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767689074721,"gmtModify":1767953554772,"symbols":["09860","300430"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":511,"likeCount":2,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/519020428329376","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":113,"displayRows":4,"foldSize":0,"authorId":"4214309434755002"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.516165331198312","cardData":[{"tweetId":"516165331198312","author":{"authorId":"4111461471939460","idStr":"4111461471939460","name":"方新侠YY","avatar":"https://static.tigerbbs.com/9c047f61fcd0850109e2b3261bd2ddc4","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a> 在底部区域分批买,在顶部区域分批卖,好过纠结于具体某一个点位的完美。","plainDigest":"$艾迪康控股(09860)$ 在底部区域分批买,在顶部区域分批卖,好过纠结于具体某一个点位的完美。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767067046707,"gmtModify":1767067048497,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":330,"likeCount":1,"liked":false,"collected":false,"commentCount":1,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/516165331198312","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":84,"displayRows":4,"foldSize":0,"authorId":"4111461471939460"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.513955781833328","cardData":[{"tweetId":"513955781833328","author":{"authorId":"4214529501700820","idStr":"4214529501700820","name":"外资不跑","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a> AI医疗看病比人准,每次从医院回来,我都要去deepseek问一下医生给开的药对不对。 ","plainDigest":"$艾迪康控股(09860)$ AI医疗看病比人准,每次从医院回来,我都要去deepseek问一下医生给开的药对不对。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1766503567082,"gmtModify":1766503568895,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":328,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/513955781833328","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":92,"displayRows":4,"foldSize":0,"authorId":"4214529501700820"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.516570265584856","cardData":[{"tweetId":"516570265584856","author":{"authorId":"4151027865885450","idStr":"4151027865885450","name":"艾迪康","avatar":"https://static.tigerbbs.com/894dcd837ee3c84e52e3a5e19e3d4f93","userType":5,"introduction":"艾迪康为中国三大ICL服务提供商之一,主要为医院及体检中心提供丰富的一流检验服务。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":546,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"坚守高品质,共促新发展|艾迪康旗下元德友勤实验室顺利通过 CNAS ISO 15189 复评审","digest":" 2025年12月19日至21日,苏州元德友勤医学检验实验室成功接受并通过中国合格评定国家认可委员会(CNAS)组织的ISO 15189 医学实验室质量与能力复评审。这是该实验室第三次获得此项权威认可,标志着其质量管理体系与技术服务能力持续符合国际标准,具备稳定可靠的医学检验服务水平。 关于ISO 15189 ISO 15189 是全球医学实验室质量与能力的核心认可标准,覆盖样本接收、检验实施、报告出具全流程,对人员资质、设备管理、检验方法、质量控制、生物安全、信息管理等关键环节均有明确规范,是保障检验结果准确性、可靠性的重要依据,也是医学检验机构专业化、规范化运营的重要标志。 复评审实施情况 本次复评审由主任评审员、安徽医科大学第一附属医院李涛教授,技术评审员、广州中医药大学第一附属医院刘基铎教授,技术评审员、南京大学医学院附属苏州医院严茹红教授组成评审组,依据 CNAS-CL02:2023《医学实验室质量和能力认可准则》及相关应用要求开展全面评审。 ▲评审现场 评审启动会上,评审组组长李涛教授介绍了评审范围、流程及纪律要求,苏州元德友勤医学检验实验室总经理陈军先生和实验室主任岑建农先生分别就实验室概况及 ISO 15189质量管理体系的建设与运行情况作了汇报,并表示将全力配合评审工作,认真落实专家提出的改进建议。 评审期间,专家组通过查阅实验室质量管理体系文件、设备校准记录、人员培训档案、质量控制数据等相关资料,深入实验室各操作区域,实地考察设施环境、实验操作流程,并进行现场提问与实操考核,全面评估了检验前、中、后各环节的质量控制情况。此外,评审组还走访了两家合作医疗机构,了解样品采集、传递、报告反馈等环节的衔接情况,听取临床医护人员对实验室服务质量的评价,进一步验证了实验室在终端服务中的专业表现。 ▲现场评审及走访合作医疗机构 经全面评审","plainDigest":" 2025年12月19日至21日,苏州元德友勤医学检验实验室成功接受并通过中国合格评定国家认可委员会(CNAS)组织的ISO 15189 医学实验室质量与能力复评审。这是该实验室第三次获得此项权威认可,标志着其质量管理体系与技术服务能力持续符合国际标准,具备稳定可靠的医学检验服务水平。 关于ISO 15189 ISO 15189 是全球医学实验室质量与能力的核心认可标准,覆盖样本接收、检验实施、报告出具全流程,对人员资质、设备管理、检验方法、质量控制、生物安全、信息管理等关键环节均有明确规范,是保障检验结果准确性、可靠性的重要依据,也是医学检验机构专业化、规范化运营的重要标志。 复评审实施情况 本次复评审由主任评审员、安徽医科大学第一附属医院李涛教授,技术评审员、广州中医药大学第一附属医院刘基铎教授,技术评审员、南京大学医学院附属苏州医院严茹红教授组成评审组,依据 CNAS-CL02:2023《医学实验室质量和能力认可准则》及相关应用要求开展全面评审。 ▲评审现场 评审启动会上,评审组组长李涛教授介绍了评审范围、流程及纪律要求,苏州元德友勤医学检验实验室总经理陈军先生和实验室主任岑建农先生分别就实验室概况及 ISO 15189质量管理体系的建设与运行情况作了汇报,并表示将全力配合评审工作,认真落实专家提出的改进建议。 评审期间,专家组通过查阅实验室质量管理体系文件、设备校准记录、人员培训档案、质量控制数据等相关资料,深入实验室各操作区域,实地考察设施环境、实验操作流程,并进行现场提问与实操考核,全面评估了检验前、中、后各环节的质量控制情况。此外,评审组还走访了两家合作医疗机构,了解样品采集、传递、报告反馈等环节的衔接情况,听取临床医护人员对实验室服务质量的评价,进一步验证了实验室在终端服务中的专业表现。 ▲现场评审及走访合作医疗机构 经全面评审","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1767145074678,"gmtModify":1767146173088,"symbols":["09860"],"themeIds":["cfc6b1c6993d42dc800bf43cf2977999"],"themes":[{"themeId":"cfc6b1c6993d42dc800bf43cf2977999","themeType":0,"name":"【年度复盘】收官在即!聊聊今年的投资"}],"popularizeThemeFlag":false,"imageCount":8,"images":[{"url":"https://static.tigerbbs.com/b84e40a24efad2ed0c9a5659ca8a0197","width":"1079","height":"719"},{"url":"https://static.tigerbbs.com/3e2ca0e616a443a9a9e7c7998a79aa47","width":"1079","height":"719"},{"url":"https://static.tigerbbs.com/cfa31b37179cb1ed6d0307d77c61f921","width":"749","height":"499"}],"repostCount":0,"viewCount":22756,"likeCount":1,"liked":false,"collected":false,"commentCount":1,"hotComments":[{"id":"516803230085696","author":{"authorId":"3479274811665394","idStr":"3479274811665394","name":"lilk2road","avatar":"https://static.laohu8.com/picture176","userType":8,"introduction":"运营账号","crmLevel":1,"crmLevelSwitch":0,"fanSize":56,"starInvestorFlag":false},"content":"质量稳如泰山,艾迪康真牛!","plainContent":"质量稳如泰山,艾迪康真牛!","likeCount":0,"commentType":"valid","coins":0}],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/516570265584856","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":2363,"displayRows":4,"foldSize":0,"authorId":"4151027865885450"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.511331551048928","cardData":[{"tweetId":"511331551048928","author":{"authorId":"4111461471939460","idStr":"4111461471939460","name":"方新侠YY","avatar":"https://static.tigerbbs.com/9c047f61fcd0850109e2b3261bd2ddc4","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a> 高盛喊话诊断板块回暖,艾迪康是同行里业绩最好的","plainDigest":"$艾迪康控股(09860)$ 高盛喊话诊断板块回暖,艾迪康是同行里业绩最好的","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765863773098,"gmtModify":1765863775253,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":592,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/511331551048928","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":64,"displayRows":4,"foldSize":0,"authorId":"4111461471939460"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.508980849172792","cardData":[{"tweetId":"508980849172792","author":{"authorId":"4107239966895660","idStr":"4107239966895660","name":"向阳花之光","avatar":"https://static.tigerbbs.com/e322d38c22fa6cc88f0c102424c4a365","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a>砸2亿美金拿下全球肿瘤CRO巨头冠科生物,直接切入药物研发黄金赛道!","plainDigest":"$艾迪康控股(09860)$ 砸2亿美金拿下全球肿瘤CRO巨头冠科生物,直接切入药物研发黄金赛道!","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765249783368,"gmtModify":1765249785125,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":473,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/508980849172792","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":81,"displayRows":4,"foldSize":0,"authorId":"4107239966895660"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.509480370086088","cardData":[{"tweetId":"509480370086088","author":{"authorId":"4095252017433400","idStr":"4095252017433400","name":"六爷说股","avatar":"https://static.tigerbbs.com/44b3b252110035fe5ff631c229f8ac83","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"强强联合!艾迪康与**云深化合作,“技术+场景”共筑智慧医疗新生态","digest":"12月8日,杭州艾迪康医学检验中心有限公司(以下简称“艾迪康”)与**云计算技术有限公司(以下简称“**云”)在**练秋湖相聚并签署框架合作协议,艾迪康副总裁及首席信息官罗震、艾迪康副总裁及营销中心负责人葛顺、**云中国区公有云解决方案销售部部长庄乾锋等共同出席本次签约仪式。 双方围绕医疗行业数字化转型痛点、AI技术赋能临床质控等场景展开深入探讨,充分交流了在企业数字化建设、AI技术医疗场景应用等方面的经验与见解。 **云中国区公有云解决方案销售部部长庄乾锋表示,**云始终以“技术驱动、开放共赢”为使命,致力于为千行百业提供领先的数字化解决方案。杭州艾迪康作为医疗健康领域的创新先锋,在精准医疗与智能化服务领域成果卓著。此次合作,是双方对“技术赋能产业”这一愿景的深度契合。通过**云的云计算、AI及大数据能力,与艾迪康的行业专长结合,我们必将为医疗行业打造更高效、更智能的数字化转型范式。 **云中国区公有云解决方案销售部部长庄乾锋 艾迪康副总裁及首席信息官罗震表示,“数字化转型正在重塑医疗行业的服务范式。我们期待通过此次合作,构建集数据安全治理、智能算法引擎与云端协同能力于一体的新一代医疗平台,使前沿技术深度赋能临床实践,提升医疗服务的可及性、准确性与普惠价值。” 艾迪康副总裁及首席信息官罗震 **云咨询首席专家王健对**AI战略与行业实践成果做了分享,系统阐述了**云服务、**AI等基础设施在各行业的赋能价值,为双方后续合作搭建了清晰的技术路径。 签约现场,艾迪康公司发布了基于**云技术支撑的艾迪康医疗AI大模型“问医”及智能体应用产品方案。这是艾迪康“场景验证”能力与**云“技术赋能”优势深度融合的成果,充分体现了艾迪康在AI医疗创新应用方面的前瞻布局与高效落地能力。 此次合作是艾迪康与**云深化互信、推进业务合作的重要里程碑,不仅实现了双方在技术、管理、市场等多维度的全","plainDigest":"12月8日,杭州艾迪康医学检验中心有限公司(以下简称“艾迪康”)与**云计算技术有限公司(以下简称“**云”)在**练秋湖相聚并签署框架合作协议,艾迪康副总裁及首席信息官罗震、艾迪康副总裁及营销中心负责人葛顺、**云中国区公有云解决方案销售部部长庄乾锋等共同出席本次签约仪式。 双方围绕医疗行业数字化转型痛点、AI技术赋能临床质控等场景展开深入探讨,充分交流了在企业数字化建设、AI技术医疗场景应用等方面的经验与见解。 **云中国区公有云解决方案销售部部长庄乾锋表示,**云始终以“技术驱动、开放共赢”为使命,致力于为千行百业提供领先的数字化解决方案。杭州艾迪康作为医疗健康领域的创新先锋,在精准医疗与智能化服务领域成果卓著。此次合作,是双方对“技术赋能产业”这一愿景的深度契合。通过**云的云计算、AI及大数据能力,与艾迪康的行业专长结合,我们必将为医疗行业打造更高效、更智能的数字化转型范式。 **云中国区公有云解决方案销售部部长庄乾锋 艾迪康副总裁及首席信息官罗震表示,“数字化转型正在重塑医疗行业的服务范式。我们期待通过此次合作,构建集数据安全治理、智能算法引擎与云端协同能力于一体的新一代医疗平台,使前沿技术深度赋能临床实践,提升医疗服务的可及性、准确性与普惠价值。” 艾迪康副总裁及首席信息官罗震 **云咨询首席专家王健对**AI战略与行业实践成果做了分享,系统阐述了**云服务、**AI等基础设施在各行业的赋能价值,为双方后续合作搭建了清晰的技术路径。 签约现场,艾迪康公司发布了基于**云技术支撑的艾迪康医疗AI大模型“问医”及智能体应用产品方案。这是艾迪康“场景验证”能力与**云“技术赋能”优势深度融合的成果,充分体现了艾迪康在AI医疗创新应用方面的前瞻布局与高效落地能力。 此次合作是艾迪康与**云深化互信、推进业务合作的重要里程碑,不仅实现了双方在技术、管理、市场等多维度的全","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765422794923,"gmtModify":1765423390472,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":4,"images":[{"url":"https://static.tigerbbs.com/d16b13565189fd9eba93dd6eda4dddd8","width":"650","height":"433"},{"url":"https://static.tigerbbs.com/df698a8703f05fd7ef38b8bf6e3fd208","width":"650","height":"433"},{"url":"https://static.tigerbbs.com/8872038f30ea14bc958720e46fc6319b","width":"650","height":"433"}],"repostCount":0,"viewCount":453,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/509480370086088","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":1755,"displayRows":4,"foldSize":0,"authorId":"4095252017433400"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.507608384864352","cardData":[{"tweetId":"507608384864352","author":{"authorId":"4111461471939460","idStr":"4111461471939460","name":"方新侠YY","avatar":"https://static.tigerbbs.com/9c047f61fcd0850109e2b3261bd2ddc4","userType":1,"introduction":"","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"","digest":"<a href=\"https://laohu8.com/S/09860\">$艾迪康控股(09860)$ </a> 这一秒不放弃,下一秒就有希望。","plainDigest":"$艾迪康控股(09860)$ 这一秒不放弃,下一秒就有希望。","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1764903561743,"gmtModify":1764903563548,"symbols":["09860"],"themeIds":[],"popularizeThemeFlag":false,"imageCount":0,"images":[],"repostCount":0,"viewCount":611,"likeCount":1,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":false,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/507608384864352","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":47,"displayRows":4,"foldSize":0,"authorId":"4111461471939460"}],"position":0},{"cardType":"TWEET","cardId":"TWEET.509521824112688","cardData":[{"tweetId":"509521824112688","author":{"authorId":"4151027865885450","idStr":"4151027865885450","name":"艾迪康","avatar":"https://static.tigerbbs.com/894dcd837ee3c84e52e3a5e19e3d4f93","userType":5,"introduction":"艾迪康为中国三大ICL服务提供商之一,主要为医院及体检中心提供丰富的一流检验服务。","crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":546,"starInvestorFlag":false,"userFollowAuthorFlag":false,"authorFollowUserFlag":false},"userFollowAuthorFlag":false,"authorFollowUserFlag":false,"title":"艾迪康与**云深化合作,共筑“技术+场景”驱动的智慧医疗新生态","digest":" 12月8日,杭州艾迪康医学检验中心有限公司(以下简称“艾迪康”)与**云计算技术有限公司(以下简称“**云”)正式签署合作协议。艾迪康副总裁及首席信息官罗震、副总裁及营销中心负责人葛顺等公司高管,与**中国区公有云解决方案部部长庄乾锋等高层代表共同出席签约仪式并进行深度对话,标志着双方在智慧医疗领域的协同创新步入全新阶段。 ▲艾迪康副总裁及首席信息官罗震 ▲**中国区公有云解决方案部部长庄乾锋 当前,医疗健康产业正处在数字化转型的关键时期,艾迪康与**云此次携手合作,共同开启了以AI技术为引擎的智慧医疗新篇章。此次合作不仅是技术能力与行业场景的深度融合,更是医学检验服务从传统模式向智能化、生态化演进的重要里程碑。 创新驱动:共建医疗数字化新基座 在人工智能技术加速重构医疗体系的今天,艾迪康始终站在行业创新的前沿。依托在医学检验领域超过二十年的专业积淀,艾迪康拥有覆盖全国的服务网络与多维度临床数据资源。此次与**云达成合作,旨在共同打造面向未来的医疗智能化基础设施。 艾迪康副总裁及首席信息官罗震表示:“数字化转型正在重塑医疗行业的服务范式。我们期待通过此次合作,构建集数据安全治理、智能算法引擎与云端协同能力于一体的新一代医疗平台,使前沿技术深度赋能临床实践,提升医疗服务的可及性、准确性与普惠价值。” ▲签约领导合影 协同成果:技术赋能引领服务升级 基于双方在技术积累与场景探索上的长期准备,本次合作已实现阶段性成果。签约仪式现场,艾迪康正式发布了基于**云技术支持的“问医”医疗大模型及多款智能体解决方案。这些成果是艾迪康“场景验证”能力与**云“技术赋能”优势深度融合的体现,展现了艾迪康在AI医疗创新应用上的前瞻布局与高效实施能力。 智能质控系统可对检验全流程进行实时监测与预警,借助AI算法自动识别数据异常,显著提升","plainDigest":" 12月8日,杭州艾迪康医学检验中心有限公司(以下简称“艾迪康”)与**云计算技术有限公司(以下简称“**云”)正式签署合作协议。艾迪康副总裁及首席信息官罗震、副总裁及营销中心负责人葛顺等公司高管,与**中国区公有云解决方案部部长庄乾锋等高层代表共同出席签约仪式并进行深度对话,标志着双方在智慧医疗领域的协同创新步入全新阶段。 ▲艾迪康副总裁及首席信息官罗震 ▲**中国区公有云解决方案部部长庄乾锋 当前,医疗健康产业正处在数字化转型的关键时期,艾迪康与**云此次携手合作,共同开启了以AI技术为引擎的智慧医疗新篇章。此次合作不仅是技术能力与行业场景的深度融合,更是医学检验服务从传统模式向智能化、生态化演进的重要里程碑。 创新驱动:共建医疗数字化新基座 在人工智能技术加速重构医疗体系的今天,艾迪康始终站在行业创新的前沿。依托在医学检验领域超过二十年的专业积淀,艾迪康拥有覆盖全国的服务网络与多维度临床数据资源。此次与**云达成合作,旨在共同打造面向未来的医疗智能化基础设施。 艾迪康副总裁及首席信息官罗震表示:“数字化转型正在重塑医疗行业的服务范式。我们期待通过此次合作,构建集数据安全治理、智能算法引擎与云端协同能力于一体的新一代医疗平台,使前沿技术深度赋能临床实践,提升医疗服务的可及性、准确性与普惠价值。” ▲签约领导合影 协同成果:技术赋能引领服务升级 基于双方在技术积累与场景探索上的长期准备,本次合作已实现阶段性成果。签约仪式现场,艾迪康正式发布了基于**云技术支持的“问医”医疗大模型及多款智能体解决方案。这些成果是艾迪康“场景验证”能力与**云“技术赋能”优势深度融合的体现,展现了艾迪康在AI医疗创新应用上的前瞻布局与高效实施能力。 智能质控系统可对检验全流程进行实时监测与预警,借助AI算法自动识别数据异常,显著提升","sourceLanguage":"CN","currentLanguage":"CN","editable":false,"auditStatus":"PASSED","topFlag":false,"totalScore":0,"gmtCreate":1765432914523,"gmtModify":1765432930462,"symbols":["09860"],"themeIds":["3d2922b3973342b58efe2b46b8778a28"],"themes":[{"themeId":"3d2922b3973342b58efe2b46b8778a28","themeType":0,"name":"老虎财报季"}],"popularizeThemeFlag":false,"imageCount":4,"images":[{"url":"https://static.tigerbbs.com/0f59544a4d4390f233b5d9ec27a9201a","width":"1080","height":"720"},{"url":"https://static.tigerbbs.com/4daf95be1b6f0e821e035988dd113f89","width":"1080","height":"720"},{"url":"https://static.tigerbbs.com/e33936d9a178dff8997162b92f33beec","width":"1268","height":"846"}],"repostCount":0,"viewCount":22526,"likeCount":0,"liked":false,"collected":false,"commentCount":0,"hotComments":[],"voteFlag":false,"rewardFlag":false,"videoFlag":false,"articleFlag":false,"paperFlag":true,"essentialFlag":false,"highlightedFlag":false,"shareLink":"https://laohu8.com/post/509521824112688","orderFlag":false,"starInvestorRankings":[],"featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":3216,"displayRows":4,"foldSize":0,"authorId":"4151027865885450"}],"position":0}],"size":10},"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20127229","market":"hk","labels":[],"media":"港交所","original_id":"N.HK8qcU3XSpqb","pdf_url":"https://static.tigerbbs.com/48742dd21ddc4fa193bfbdfd4d403b24","pub_time":1756974720000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025 中期报告","symbol":"09860","title":"2025 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0904/2025090400592_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-04 16:32","pubTimestamp":1756974720,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20026291","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7W2RmXZjUH","pdf_url":"https://static.tigerbbs.com/cc976c038f4f4ea397060e6e41701a11","pub_time":1755851460000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年6月30日止六个月之中期业绩公告","symbol":"09860","title":"截至2025年6月30日止六个月之中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0822/2025082200344_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-08-22 16:31","pubTimestamp":1755851460,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19687385","market":"hk","labels":[],"media":"港交所","original_id":"N.HK7ySYFzjdR4","pdf_url":"https://static.tigerbbs.com/b814470e99bb4cfdbe1a02e64091a77b","pub_time":1747996320000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权","symbol":"09860","title":"补充公告 - 须予披露交易涉及根据一般授权发行代价股份以收购目标公司全部股权","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0523/2025052301196_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 代价发行 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-05-23 18:32","pubTimestamp":1747996320,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19603677","market":"hk","labels":[],"media":"港交所","original_id":"N.HK3H853NAEbH","pdf_url":"https://static.tigerbbs.com/c06fe01de56f43f981b68567b705fc77","pub_time":1746528900000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权","symbol":"09860","title":"须予披露交易 - 涉及根据一般授权发行代价股份以收购目标公司全部股权","titleType":"须予披露的交易","type":"hkTrade","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0506/2025050602420_c.pdf","us_notice_code":"公告及通告 - [须予披露的交易 / 代价发行 / 根据一般性授权发行股份]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易相关","type_name_en":"Transaction Related","titleTypeEn":"","event_type":"important_notice","event_name":"须予披露的交易","pubTime":"2025-05-06 18:55","pubTimestamp":1746528900,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19597967","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEo8TY2XvmQ","pdf_url":"https://static.tigerbbs.com/7ca5dbae815b4e399fcf13655d0a1acc","pub_time":1746441240000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告","symbol":"09860","title":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议续聘核数师及2025年股东周年大会通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0505/2025050500020_c.pdf","us_notice_code":"通函 - [在股东批准的情况下重选或委任董事 / 回购股份的说明函件 / 一般性授权]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2025-05-05 18:34","pubTimestamp":1746441240,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19491661","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEx9zzMSh1b","pdf_url":"https://static.tigerbbs.com/13ef2c62d20843a1ad97cdfe80faf8f1","pub_time":1745535660000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024 年度报告","symbol":"09860","title":"2024 年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0425/2025042500092_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-04-25 07:01","pubTimestamp":1745535660,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"19320874","market":"hk","labels":[],"media":"港交所","original_id":"N.HKGB2fjFgogz","pdf_url":"https://static.tigerbbs.com/c18b5790e4a945cd8a12533a1b409d9c","pub_time":1743409920000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年12月31日止年度之年度业绩公告","symbol":"09860","title":"截至2024年12月31日止年度之年度业绩公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0331/2025033100496_c.pdf","us_notice_code":"公告及通告 - [末期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-03-31 16:32","pubTimestamp":1743409920,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18628725","market":"hk","labels":[],"media":"港交所","original_id":"N.HKG1TpP1gfaB","pdf_url":"https://static.tigerbbs.com/b16ec890af8f4624b7788927dbc5d2d1","pub_time":1726749240000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2024 中期报告","symbol":"09860","title":"2024 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0919/2024091901547_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-09-19 20:34","pubTimestamp":1726749240,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18558369","market":"hk","labels":[],"media":"港交所","original_id":"N.HKB8e1fuRKXN","pdf_url":"https://static.tigerbbs.com/77908cbfff174581acabce1428a46a89","pub_time":1725006600000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2024年6月30日止六个月之中期业绩公告","symbol":"09860","title":"截至2024年6月30日止六个月之中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0830/2024083000546_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2024-08-30 16:30","pubTimestamp":1725006600,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18049055","market":"hk","labels":[],"media":"港交所","original_id":"N.HKw1uprqHdc8","pdf_url":"https://static.tigerbbs.com/dad4dd4f1db641a4a59ebdeb33ab194b","pub_time":1714348800000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告","symbol":"09860","title":"建议授出购回股份及发行新股份之一般授权及建议重选退任董事及建议委任非执行董事及建议续聘核数师及2024年股东周年大会通告","titleType":"股份购回","type":"hkShares","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0429/2024042900166_c.pdf","us_notice_code":"通函 - [在股东批准的情况下重选或委任董事 / 回购股份的说明函件 / 一般性授权]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"股权股本","type_name_en":"Equity Change","titleTypeEn":"Share Repurchase","event_type":"important_notice","event_name":"股份购回","pubTime":"2024-04-29 08:00","pubTimestamp":1714348800,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"18049017","market":"hk","labels":[],"media":"港交所","original_id":"N.HK9L3M9jpzxE","pdf_url":"https://static.tigerbbs.com/c55bb1222fb44d99bd6ee8fbbcfede6c","pub_time":1714348560000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2023 年度报告","symbol":"09860","title":"2023 年度报告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0429/2024042900126_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [年报]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2024-04-29 07:56","pubTimestamp":1714348560,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"17768188","market":"hk","labels":[],"media":"港交所","original_id":"N.HKFEyBfD37aR","pdf_url":"https://static.tigerbbs.com/df8e2684de2045ffb13d01bff80e3432","pub_time":1711614600000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2023年12月31日止年度之年度业绩公告","symbol":"09860","title":"截至2023年12月31日止年度之年度业绩公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2024/0328/2024032800753_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 暂停办理过户登记手续或更改暂停办理过户日期]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2024-03-28 16:30","pubTimestamp":1711614600,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"16998686","market":"hk","labels":[],"media":"港交所","original_id":"N.HKCMBjQGMKtn","pdf_url":"https://static.tigerbbs.com/b08e2368e8214fb7a91677f86fd55f29","pub_time":1695630660000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2023 中期报告","symbol":"09860","title":"2023 中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2023/0925/2023092500300_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2023-09-25 16:31","pubTimestamp":1695630660,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"16837125","market":"hk","labels":[],"media":"港交所","original_id":"N.HKzEVQ86wd28","pdf_url":"https://static.tigerbbs.com/a8b6972dbfae4007ab808c01827b49be","pub_time":1692779400000,"showTitleType":false,"size":0,"source":"hk_ex_news","summary":"截至2023年6月30日止六个月之中期业绩公告","symbol":"09860","title":"截至2023年6月30日止六个月之中期业绩公告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2023/0823/2023082300282_c.pdf","us_notice_code":"公告及通告 - [中期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2023-08-23 16:30","pubTimestamp":1692779400,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"16588691","market":"hk","labels":[],"media":"港交所","original_id":"N.HKEoRw2BQmXa","pdf_url":"https://static.tigerbbs.com/7a00380fc99a46f2b17d6143c3b178d6","pub_time":1687126740000,"showTitleType":false,"size":0,"source":"hk_ex_news","summary":"绿色申请表格","symbol":"09860","title":"绿色申请表格","titleType":"股份发售","type":"hkIPO","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2023/0619/2023061900008_c.pdf","us_notice_code":"上市文件 - [发售以供认购]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"上市文件","type_name_en":"Listing Document","titleTypeEn":"Shares Subscription","event_type":"important_notice","event_name":"股份发售","pubTime":"2023-06-19 06:19","pubTimestamp":1687126740,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.adicon.com.cn","stockEarnings":[{"period":"1week","weight":0.0851},{"period":"1month","weight":0.0921},{"period":"3month","weight":-0.1761},{"period":"6month","weight":-0.2897},{"period":"1year","weight":-0.2555},{"period":"ytd","weight":0.2057}],"compareEarnings":[{"period":"1week","weight":0.0234},{"period":"1month","weight":0.054},{"period":"3month","weight":0.0633},{"period":"6month","weight":0.0813},{"period":"1year","weight":0.3751},{"period":"ytd","weight":0.0474}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"艾迪康控股有限公司是一家主要提供独立医学实验室(ICL)的控股公司。该公司提供医学检验、临床试验、科研服务、健康管理及病理会诊服务。该公司重点发展感染性疾病、妇女健康、实体肿瘤、围产&儿童中心、血液等核心疾病领域,覆盖内科、儿科、妇产科、肿瘤科、神经科等众多科目。","exchange":"SEHK","name":"艾迪康控股","nameEN":"ADICON HOLDINGS"},"aProfile":null}}}